3C-FP, also known as 4-(3-fluoropropoxy)-3,5-dimethoxyamphetamine or as ñ-methylfluoroproscaline (3C-fluoroproscaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to TMA (3,4,5-TMA). It is the amphetamine (ñ-methyl) derivative of fluoroproscaline (FP).
According to Daniel Trachsel, 3C-FP's dose is 25mg or more orally and its duration is approximately 8hours. The specific effects of 3C-FP were not described.
The receptor interactions of 3C-FP have been studied. It shows affinity for the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors (K<sub>i</sub> = 2,600âÂÂ4,581nM and 4,400nM) and is a potent partial agonist of the serotonin 5-HT<sub>2A</sub> receptor ( = 57nM; = 62%) but not of the serotonin 5-HT<sub>2B</sub> receptor ( = >10,000nM).
The chemical synthesis of 3C-FP has been described.
3C-FP was first described in the scientific literature by Trachsel in 2002. Subsequently, its pharmacology as well as its properties in humans were reported by Trachsel and colleagues in 2012, 2013, and 2021.